文献速递免疫规划

新型高密度微投影阵列贴片(Nanopatch™)经人皮肤递送流感疫苗的安全性、耐受性、可接受性与免疫原性

Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
PubMed 文献 · Vaccine · 2018-05-17

这项随机、部分盲法、安慰剂对照试验首次在人体使用Nanopatch™递送流感疫苗。健康志愿者单次接种后,贴片接种安全可接受,不良事件均为轻中度,抗原接种组第7天和第21天血凝抑制抗体滴度较基线显著升高(p<0.0001),各组间无统计学差异(p>0.05)。

要点

  • Nanopatch™贴片接种流感疫苗安全可接受,不良事件均为轻中度。
  • 55%的贴片接种者偏好Nanopatch™,而24%偏好既往肌注经验。
  • 抗原接种组第7天和第21天血凝抑制抗体滴度较基线显著升高(p<0.0001)。

核心结论

  • 使用Nanopatch™进行流感疫苗接种在本次首次人体研究中看似安全且可接受,并诱导了与肌内注射接种相似的免疫应答。

研究设计与样本

  • 随机、部分盲法、安慰剂对照试验,首次在人体使用Nanopatch™递送疫苗;健康志愿者单次接种。
  • 分组:NP-HA/FA组n=15(15 µg HA,前臂掌侧);NP-HA/UA组n=15(15 µg HA,上臂);IM-HA/D组n=15(Fluvax® 2016含15 µg同种H1N1 HA抗原,三角肌肌内注射);NP-placebo/FA组n=5;NP-placebo/UA组n=5;IM-placebo/D组n=5。

主要发现

  • 所有不良事件均为轻中度。
  • 接受贴片接种(抗原或安慰剂)的受试者中55%偏好Nanopatch™,而24%偏好既往肌内注射针筒经验。
  • 抗原接种组第7天和第21天HAI滴度较基线有统计学升高(p<0.0001),治疗组间无统计学差异(p>0.05),尽管组样本量小。
  • 第21天HAI几何平均滴度:NP-HA/FA组335(189-593 95%CI),NP-HA/UA组160(74-345 95%CI),IM-HA/D组221(129-380 95%CI);MN试验呈现相似应答模式。
  • 应用部位反应为轻中度,流感疫苗贴片组比安慰剂或肌内注射组更明显。

局限性

  • 原文指出组样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) is a microarray skin patch comprised of a high-density array of microprojections dry-coated with vaccine that is being developed to address these shortcomings. Here we report a randomised, partly-blinded, placebo-controlled trial that represents the first use in humans of the NP to deliver a vaccine. METHODS: Healthy volunteers were vaccinated once with one of the following: (1) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 µg haemagglutinin (HA) per dose), applied to the volar forearm (NP-HA/FA), n = 15; (2) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 µg HA per dose), applied to the upper arm (NP-HA/UA), n = 15; (3) Fluvax® 2016 containing 15 µg of the same H1N1 HA antigen injected intramuscularly (IM) into the deltoid (IM-HA/D), n = 15; (4) NPs coated with excipients only, applied to the volar forearm (NP-placebo/FA), n = 5; (5) NPs coated with excipients only applied to the upper arm (NP-placebo/UA), n = 5; or (6) Saline injected IM into the deltoid (IM-placebo/D), n = 5. Antibody responses at days 0, 7, and 21 were measured by haemagglutination inhibition (HAI) and microneutralisation (MN) assays. FINDINGS: NP vaccination was safe and acceptable; all adverse events were mild or moderate. Most subjects (55%) receiving patch vaccinations (HA or placebo) preferred the NP compared with their past experience of IM injection with N&S (preferred by 24%). The antigen-vaccinated groups had statistically higher HAI titres at day 7 and 21 compared with baseline (p < 0.0001), with no statistical differences between the treatment groups (p > 0.05), although the group sizes were small. The geometric mean HAI titres at day 21 for the NP-HA/FA, NP-HA/UA and IM-HA/D groups were: 335 (189-593 95% CI), 160 (74-345 95% CI), and 221 (129-380 95% CI) respectively. A similar pattern of responses was seen with the MN assays. Application site reactions were mild or moderate, and more marked with the influenza vaccine NPs than with the placebo or IM injection. INTERPRETATION: Influenza vaccination using the NP appeared to be safe, and acceptable in this first time in humans study, and induced similar immune responses to vaccination by IM injection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fernando GJP, Hickling J, Jayashi Flores CM, et al. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 2018. PMID: 29779922. doi:10.1016/j.vaccine.2018.05.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。